Creative Medical Technology Holdings, Inc. (CELZ) Key Metrics
CELZ valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.6M
- Enterprise value
- −$2.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.91
CELZ key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCELZ returns How much profit the business earns on the capital it uses.
CELZ financial health Debt, liquidity and how easily interest is covered.
CELZ efficiency & capital use Working capital cycle and where the cash goes.
CELZ valuation history
CELZ returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CELZ debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CELZ cash returned to shareholders
CELZ price vs earnings per share
CELZ key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.7M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$2.5M | — | — | — | — | — | — | — | — | — |
| Price / sales | 778.4 | — | — | — | — | — | — | — | — | — |
| Price / book | 0.6 | — | — | — | — | — | — | — | — | — |
| EV / sales | -420.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −128.4% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −125.4% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.2% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.96 | $2.31 | $4.61 | $3.81 | $22.10 | $139.00 | $225.00 | $7,425.00 | $10,125.00 | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$2.52 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$2.46 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$2.46 | — | — | — | — | — | — | — | — | — |
| Cash per share | $3.03 | — | — | — | — | — | — | — | — | — |
| Book value per share | $3.15 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $2.98 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.01 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 2.4M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −86.5% | −65.8% | −40.3% | −77.8% | — | — | — | — | — | — |
| Return on assets (ROA) | −82.8% | −63.2% | −35.4% | −66.6% | 320.6% | — | — | — | — | −474.7% |
| Return on tangible assets | −81.0% | −89.5% | −51.5% | −54.1% | 178.9% | — | — | — | — | −345.3% |
| Free cash flow margin | — | — | — | — | — | −416.1% | −733.0% | −845.9% | — | — |
| Income quality (OCF / net income) | — | — | — | — | −0.12 | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $14,194 | $14,194 | $14,194 | $14,194 | $14,194 | $788,701 | $1.1M | $682,056 | $513,463 | $125,000 |
| Cash & short-term investments | $7.2M | $5.9M | $10.0M | $18.4M | $10.7M | $98,012 | $88,648 | $304,056 | $13,697 | $221,868 |
| Net debt | −$7.2M | −$5.9M | −$10.0M | −$18.4M | −$10.7M | $690,689 | $973,618 | $378,000 | $499,766 | −$96,868 |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.10 | 2.00 | 1.43 | 2.53 | 0.39 |
| Net debt / EBITDA | — | — | — | — | −0.45 | — | — | — | — | — |
| Current ratio | 25.97 | 18.73 | 27.65 | 5.64 | 10.22 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Quick ratio | 25.97 | 18.72 | 27.64 | 5.64 | 10.21 | 0.00 | 0.01 | 0.07 | 0.01 | 0.49 |
| Interest coverage | — | — | — | -102.1 | -0.7 | -0.9 | -0.6 | -0.8 | -3.1 | -119.7 |
| Working capital | $7.1M | $5.8M | $9.9M | $15.4M | $9.7M | −$40.4M | −$8.5M | −$4.2M | −$2.4M | −$231,996 |
| Invested capital | $320,713 | $415,291 | $370,932 | −$2.5M | −$491,936 | −$39.1M | −$7.1M | −$3.6M | −$1.7M | −$254,659 |
| Tangible asset value | $7.1M | $5.8M | $9.9M | $15.4M | $9.7M | −$40.4M | −$8.5M | −$4.2M | −$2.4M | −$258,435 |
| Net current asset value | $7.1M | $5.8M | $9.9M | $15.4M | $9.7M | −$40.4M | −$8.5M | −$4.2M | −$2.4M | −$258,435 |
| Graham net-net per share | $2.92 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $4.8M | — | — | — | — | — |
| Share buybacks (net) | $10,000 | $174,964 | $270,952 | $0 | $196,751 | $0 | — | — | $0 | $0 |
| Dividend payout ratio | — | — | — | — | 24.9% | — | — | — | — | — |
| Capex / revenue | 0.1% | 1,818.2% | 1,111.1% | 0.0% | 0.0% | 152.0% | 0.0% | 0.0% | 0.0% | — |
| Capex / depreciation | 0.00 | 1.81 | 1.06 | 0.00 | 0.00 | 3.74 | 0.00 | 0.00 | 0.00 | 1.07 |
| Stock-based compensation / revenue | 58.1% | 333.2% | 407.2% | 77.6% | 678.5% | 103.5% | 0.0% | 1.5% | 3,003.3% | — |
| R&D / revenue | 37,663.3% | 21,825.2% | 21,896.0% | 7,075.5% | 124.4% | — | — | 77.7% | 5,418.4% | — |
| SG&A / revenue | 62,724.9% | 29,447.6% | 34,013.3% | 4,451.0% | 3,378.2% | 706.4% | 739.1% | 844.4% | 18,719.3% | — |
| Efficiency | ||||||||||
| Days sales outstanding | 3,168.4 | — | — | -20,755.0 | 5.2 | 6.2 | 16.8 | 21.1 | 365.1 | — |
| Days of inventory on hand | — | 364.5 | 851.1 | 134.9 | 41.4 | — | — | — | — | — |
| Days payables outstanding | 45,268.7 | 24,505.2 | 181,730.4 | 25,810.4 | 4,235.3 | 2,422.8 | 2,617.7 | 1,476.6 | 6,933.9 | 19.9 |
| Cash conversion cycle (days) | -41,917.7 | — | — | -46,430.6 | -4,188.8 | -2,416.6 | -2,601.0 | -1,455.5 | -6,568.8 | — |
| Receivables turnover | 0.12 | — | — | — | 70.63 | 58.75 | 21.78 | 17.28 | 1.00 | — |
| Payables turnover | 0.01 | 0.01 | 0.00 | 0.01 | 0.09 | 0.15 | 0.14 | 0.25 | 0.05 | 18.36 |
| Inventory turnover | — | 1.00 | 0.43 | 2.71 | 8.83 | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.26 | 0.33 | 0.37 | 0.02 | 0.00 |
| Average receivables | $52,084 | — | — | −$5.0M | $1,242 | $2,800 | $7,600 | $7,200 | $4,801 | — |
| Average payables | $272,108 | $295,405 | $1.8M | $2.0M | $556,380 | $335,842 | $326,312 | $284,702 | $151,976 | $41,732 |
| Average inventory | $1,097 | $4,394 | $8,394 | $10,530 | $5,433 | $0 | — | — | — | — |
| Intangibles / total assets | 5.2% | 8.0% | 4.1% | 2.3% | 4.7% | 86.3% | 82.2% | 34.3% | 90.9% | 31.2% |
Computed from CELZ's annual financial statements (latest annual report filed March 20, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CELZ valuation and financial ratios
Creative Medical Technology earned a return on equity of −86.5% in fiscal 2025. It ended the year with $0.0 million of debt and $7.2 million in cash and short-term investments, a net cash position of $7.2 million. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the CELZ income statement, the CELZ chart for price history, or the CELZ stock overview for the latest quote and news.
CELZ key metrics FAQ
What is Creative Medical Technology's return on equity?
Creative Medical Technology's return on equity (ROE) was −86.5% in fiscal 2025: net income of -$6.0 million on average shareholders' equity of $6.9 million.
How much debt does Creative Medical Technology have?
Creative Medical Technology had total debt of $0.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
Does Creative Medical Technology buy back its shares?
Yes. Creative Medical Technology spent $0.0 million on net share repurchases in fiscal 2025.
What is Creative Medical Technology's free cash flow yield?
Creative Medical Technology generated -$5.9 million of free cash flow in fiscal 2025, a free cash flow yield of −125.4% on its market value at year-end ($4.7 million).
What is Creative Medical Technology's current ratio?
Creative Medical Technology's current ratio was 25.97 at the end of fiscal 2025: current assets were 25.97 times current liabilities.